630424-79-2

Basic information

• Product Name: 4-FLUORO-3-METHOXYCINNAMIC ACID
• Synonyms: 4-FLUORO-3-METHOXYCINNAMIC ACID;RARECHEM BK HW 0080;Jrd-1623;3-Methoxy-4-fluorocinnamicacid;3-(4-Fluoro-3-methoxyphenyl)acrylic acid
• CAS NO: 630424-79-2
• Molecular Formula: C₁₀H₉FO₃
• Molecular Weight: 196.18
• Product Categories: Cinnamic acid;Acids & Esters;Anisoles, Alkyloxy Compounds & Phenylacetates;Fluorine Compounds;Fluorine series
• Mol File: 630424-79-2.mol

Chemical Properties

• Boiling Point: 334℃
• Flash Point: 156℃
• Appearance: /
• Density: 1.280
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.571
• Storage Temp.: 2-8°C
• PKA: 4.37±0.10(Predicted)
• CAS DataBase Reference: 4-FLUORO-3-METHOXYCINNAMIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-FLUORO-3-METHOXYCINNAMIC ACID(630424-79-2)
• EPA Substance Registry System: 4-FLUORO-3-METHOXYCINNAMIC ACID(630424-79-2)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 630424-79-2(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
4-Fluoro-3-methoxycinnamic acid is utilized as a key intermediate in the synthesis of various organic molecules. Its unique structure allows for versatile chemical reactions, making it a valuable building block in the creation of complex organic compounds.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 4-Fluoro-3-methoxycinnamic acid is employed as a starting material for the development of new drugs. Its potential biological activities have been a subject of interest, particularly in the context of discovering treatments for various medical conditions.
Used in Antifungal Applications:
4-Fluoro-3-methoxycinnamic acid is used as an antifungal agent due to its potential to inhibit the growth of fungi. This property makes it a candidate for the development of new antifungal drugs to combat fungal infections.
Used in Antimicrobial Applications:
4-Fluoro-3-methoxycinnamic acid is also used as an antimicrobial agent, showing promise in inhibiting the growth of bacteria. This characteristic positions it as a potential component in the development of new antimicrobial drugs to address bacterial resistance.
Overall, 4-Fluoro-3-methoxycinnamic acid has demonstrated its potential across multiple research and industrial applications, making it a compound of significant interest in the scientific community. Its unique structure and biological activities continue to drive research efforts aimed at harnessing its full potential in various fields.

InChI:InChI=1/C10H9FO3/c1-14-9-6-7(2-4-8(9)11)3-5-10(12)13/h2-6H,1H3,(H,12,13)/b5-3+

Upstream product

• 110-89-4 piperidine 
• 128495-46-5 4-fluoro-3-methoxybenzaldehyde 
• 141-82-2 malonic acid 

Downstream Products

• 1409964-67-5 (E)-3-(4-fluoro-3-methoxyphenyl) acryloyl azide 
• 630422-99-0 1-chloro-7-fluoro-6-methoxyisoquinoline 
• 1224104-17-9 ethyl 3-(3,5-difluoro-4-hydroxyphenyl)-2-ethoxypropanoate 
• 1224104-16-8 C₁₄H₁₇FO₃ 
• 864960-96-3 3-(4-fluoro-3-methoxyphenyl)propanoic acid 

Relevant articles and documents

Kinetics-Driven Drug Design Strategy for Next-Generation Acetylcholinesterase Inhibitors to Clinical Candidate

The acetylcholinesterase (AChE) inhibitors remain key therapeutic drugs for the treatment of Alzheimer's disease (AD). However, the low-safety window limits their maximum therapeutic benefits. Here, a novel kinetics-driven drug design strategy was employed to discover new-generation AChE inhibitors that possess a longer drug-target residence time and exhibit a larger safety window. After detailed investigations, compound 12 was identified as a highly potent, highly selective, orally bioavailable, and brain preferentially distributed AChE inhibitor. Moreover, it significantly ameliorated cognitive impairments in different mouse models with a lower effective dose than donepezil. The X-ray structure of the cocrystal complex provided a precise binding mode between 12 and AChE. Besides, the data from the phase I trials demonstrated that 12 had good safety, tolerance, and pharmacokinetic profiles at all preset doses in healthy volunteers, providing a solid basis for its further investigation in phase II trials for the treatment of AD.

HEPATITIS C VIRUS INHIBITORS

Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

GPR120 RECEPTOR AGONISTS AND USES THEREOF

GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.

ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF

Aryl GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.

GPR120 RECEPTOR AGONISTS AND USES THEREOF

GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.

HALO SUBSTITUTED BENZO`B! THIOPHENES WITH PI3K INHIBITORY ACTIVITY AS THERAPEUTIC AGENTS

The present invention provides benzo[b]thiophenes of Formula (I), wherein R3, R4, R5, R6, R7, Y, and L have any of the values defined therefor in the specification, and pharmaceutically acceptable sal